Want to see RMD full AI Analyst Report?
RMD Stock Chart & Stats
$195.27
$7.81(4.00%)
At close: 4:00 PM EDT
$195.27
$7.81(4.00%)
Day’s Range― - ―
52-Week Range$180.27 - $293.81
Previous Close$203.08
Volume1.14M
Average Volume (3M)1.50M
Market Cap
$32.95B
Enterprise Value$27.61K
Total Cash (Recent Filing)$1.47B
Total Debt (Recent Filing)$825.92M
Price to Earnings (P/E)22.2
Beta0.59
Next Earnings
Oct 22, 2026EPS Estimate
2.69Next Dividend Ex-DateN/A
Dividend Yield1.06%
Share Statistics
EPS (TTM)10.44
Shares Outstanding144,252,300
10 Day Avg. Volume1,243,506
30 Day Avg. Volume1,502,914
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)4.28
Price to Sales (P/S)4.99
P/FCF Ratio17.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$238.50Price Target Upside22.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)12.1
Revenue Forecast (FY)$5.82B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Profit GrowthMulti-year revenue expansion, improving net margins and strong gross-margin performance indicate durable demand, pricing power and operating discipline. These characteristics support continued profitability even as growth normalizes from unusually strong recent levels.
Connected Sleep-care EcosystemResMed combines devices, replacement masks and connected software, creating recurring revenue and stronger customer retention. Product adoption and digital engagement can expand the installed base while improving provider workflows and reinforcing competitive differentiation.
Strong Balance Sheet And Cash GenerationLow leverage and cash flow that consistently exceeds net income provide financial flexibility for innovation, acquisitions and shareholder returns. This reduces balance-sheet risk and gives ResMed capacity to absorb temporary product or operating disruptions.
Bears Say
Astral Safety Action Disrupts Ventilator BusinessThe safety action is a material operational and regulatory disruption rather than a temporary sentiment issue. Suspended sales and sharply lower life-support revenue can weaken the ventilator franchise, reduce near-term earnings and require remediation resources.
Growth And Margin Expansion Face Investment PressureModerating core growth combined with elevated R&D, technology and marketing investment may limit operating leverage. Although these expenditures support future products and AI capabilities, they create execution risk and could delay further margin expansion.
MatrixCare Divestiture Creates Transition RiskRefocusing on core sleep and connected care may improve strategic concentration, but divesting a business that contributed FY2026 revenue and operating profit creates execution complexity. Transition services and stranded costs could dilute benefits during the separation period.
Resmed News
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $180.26 and its highest was $293.81 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $32.95B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Oct 22, 2026 which is in 61 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Aug 06, 2026. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.893 by $0.057.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $0.66 which represents an annual dividend yield of 1.06%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.69.
How many shares outstanding does Resmed have?
Resmed has 144,252,300 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.95 in its last earnings report, beating expectations of $2.893. Following the earnings report the stock price went down -5.062%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$238.50 (22.14% Upside)
$238.50 (22.14% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 29.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.90%
12-Months-Change
Fundamentals
Return on Equity
1.06%
Trailing 12-Months
Asset Growth
9.68%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
RMD Company Deck
RMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid underlying growth and margin expansion across the core sleep business, strong full-year cash generation, material shareholder returns, and continued product and software momentum (masks, AirSense/AirCurve rollouts, GenAI MyAir, Oura partnership). Key negatives were a sizeable Astral field-safety provision and the suspension of Astral sales (driving significant ventilator revenue declines and near-term revenue/EPS headwinds), higher near-term R&D and SG&A investment, and Q4 free cash flow compression. Management provided explicit FY2027 revenue and EPS guidance, actions to return capital, and plans to prioritize high-ROI investments while actively managing the portfolio—presenting a constructive execution path despite the discrete Astral-related disruption.View all RMD earnings summariesRMD Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
RMD Stock 12 Month Forecast
Average Price Target
$238.50
▲(22.14% Upside)
Technical Analysis
Ownership Overview
0.52% Insiders
16.84% Mutual Funds
8.98% Other Institutional Investors
44.05% Public Companies and Individual Investors